• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

DBV, BioNet-Asia study needle-free pertussis booster vaccination

November 17, 2016 By Sarah Faulkner

DBV, BioNet-Asia study needle-free pertussis booster vaccinationDBV Technologies (NSDQ:DBVT) and BioNet-Asia said today that the independent Data & Safety Monitoring Board positively reviewed DBV’s needle-free vaccine patch technology, Viaskin, and that enrollment in a Phase I trial for booster immunization against pertussis will continue into the 2nd dosing cohort.

The Viaskin pertussis booster vaccination program will test the ability of DBV’s needle-free vaccine tech to epicutaneously deliver 2 different doses of BioNet’s genetically detoxified pertussis toxin, in the hopes of boosting immunity against whooping cough. The study enrolled 60 adults, ranging from 18 to 40 years old, who were vaccinated against pertussis as a child. The Viaskin patches will be applied for 48 hours, with a 2 week interval between applications.

The 1st dosing cohort received 2 applications of Viaskin at 25ųg or a placebo. Since the DSMB found no safety concerns with the 1st dosing cohort, the 2nd group of participants will receive 2 applications of Viaskin at 50ųg or a placebo. The Phase I randomized, double-blind proof of concept study is being conducted at the Clinical Research Center of the Geneva University Hospitals.

Although booster immunizations are recommended for adolescents and adults, compliance is not always high. Researchers hope a needle-free vaccine that is patient-friendly, painless and non-invasive could help increase compliance for booster immunizations.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: BioNet-Asia, DBV Technologies

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS